Pure Global
NCT06397911

Evaluate Efficacy, Pharmacokinetics, and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
Oneness Biotech Co., Ltd.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Atopic Dermatitis
Drug/Device/Intervention
FB825
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Oneness Biotech Co., Ltd.
Timeline & enrollment
Phase
Phase 2
Start date
Jul 16, 2024
End date
Dec 31, 2026
Enrollment
90 participants
Primary outcome

The percentage change from baseline in Eczema Area and Severity Index (EASI) score

Summary

This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy,
 pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with
 moderate-to-severe atopic dermatitis.

ICD-10 classifications
Atopic dermatitisAtopic dermatitis, unspecifiedOther atopic dermatitisAcute atopic conjunctivitisAllergic contact dermatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06397911
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06397911 through Pure Global AI's free database. This Phase 2 trial is sponsored by Oneness Biotech Co., Ltd. and is currently Not yet recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.